Latest Manufacturing News

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

dorsaVi has launched a multi-year collaboration with leading Asian research institutes to develop its proprietary RRAM technology at the 22-nanometer node, targeting AI-driven robotics and wearable applications.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Gale Pacific has reported a stronger-than-expected first half for FY26, delivering EBITDA of $5.7 million and positive operating cash flow despite challenging market conditions. Strategic restructuring and cost efficiencies are driving improved financial health.

5E Advanced Materials has filed a Form S-1 registration with the SEC to raise up to $30 million through a common stock offering, aiming to advance its Fort Cady boron and lithium project. The capital raise is critical as the company navigates development milestones and financial challenges.

Australian Vanadium Limited has made significant strides in its integrated vanadium project, advancing its feasibility study and securing key environmental approvals while preparing to bid for a major Western Australian battery storage project.

Syrah Resources reported a strong Q4 2025 with a 34% rise in graphite production and a strategic edge from US tariffs on Chinese imports. The company advances its Vidalia anode material facility amid growing demand for natural graphite outside China.

Way2VAT Ltd has reported a record quarterly revenue of A$2.13 million for Q4 FY25, driven by strong client growth and strategic acquisitions, setting the stage for further expansion in 2026.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.